Back

Diverse gut microbiome may improve response to immunotherapy for melanoma

Patients with melanoma who responded to immunotherapy had a more diverse gut microbiome than nonresponders, according to study results scheduled for presentation at the 2017 ASCO-SITC Clinical Immuno-Oncology Symposium.

These results suggest that modifications to the gut microbiome could potentially improve a patient’s response to anti–PD-1 therapy.

Disclosure: This study was supported by the Moon Shots Program at The University of Texas MD Anderson Cancer Center, the Melanoma Research Alliance and the Parker Institute for Cancer Immunotherapy. Please see the abstract for a list of all the researchers’ relevant financial disclosures.